Navigation Links
Thomson Reuters Partners With Sagient Research

PHILADELPHIA and LONDON, July 15 /PRNewswire/ -- Thomson Reuters today announced a partnership agreement with Sagient Research, a leading provider of biopharmaceutical institutional research. Thomson Reuters will incorporate Sagient's assessments, forecasts and approval timelines on clinical-stage drugs into the upcoming Forecast Module of Thomson Pharma(R) Partnering.

The Forecast Module, in beta testing now and planned for release in the fourth quarter, will integrate Sagient's data with comprehensive scientific and commercial analysis of the industry pipeline from Thomson Reuters, providing a combination of data to help biopharma companies and investors assess new drugs. The product will be the first on the market to put forecasting tools together with deep intelligence on the industry pipeline, enabling quicker, higher quality sales forecasts. It will provide ratings of the likelihood of drug approvals, monitor upcoming events that will affect those approvals, and provide multiple perspectives on sales forecasts, including downloadable Excel models that allow customers to tailor with their own assumptions.

"With increasing licensing activity and more scrutiny on drug development, our customers need to assess sales potential of new drugs more often than ever before," said Jon Brett-Harris, EVP of Life Sciences, Thomson Reuters. "The partnership with Sagient is an important investment in Thomson Pharma Partnering, which will put in a single place all the information required to enable quicker, better partnering and investment decisions."

"We are excited to partner with Thomson Reuters to bring our unique research to a much larger audience," said Brian Overstreet, President & CEO of Sagient Research. "Combining elements of our BioMedTracker content with Thomson Reuters' pipeline and other commercial content will address forecasting professionals' needs for multiple perspectives on a drug's potential. Customers will be able to leverage our transparent assumptions as they build their own models."

Thomson Pharma Partnering provides all of the information companies need to find and form the right partnerships, including detailed information on drugs in development, their market potential, the companies developing them, and comparable partnering deals.

About Sagient Research

Sagient Research Systems is a publisher of specialized research and data, developing, producing, and selling proprietary research products to global enterprises, including investment banks, mutual and hedge funds, pharmaceutical companies, academic institutions, and government agencies. Through the BioMedTracker research service, they monitor and forecast the commercial potential of biopharmaceutical industry pipelines. For more information, go to and

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
2. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
5. Thomson Scientific Begins Expansion of Web of Science
6. Thomson Reuters Launches New Biomarkers Solution
7. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
8. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
9. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
10. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
11. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
Post Your Comments:
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial processes, ... for in-line sensors can represent a weak spot where leaking process media is ... retractable sensor housings , which are designed to tolerate extreme process conditions. They ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):